May 09, 2025 17:00 ET | Source: Annexon Biosciences First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS)…
NEW YORK, May 6, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…
May 2, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical…
PRESS RELEASEMÉRIGNAC, FRANCE – 30 APRIL 2025 EXOSENS ANNOUNCES THE AVAILABILITY OF DOCUMENTS AND INFORMATION RELATING TO THE COMBINED GENERAL MEETING…
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a…
Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM),…
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed…
BEIJING, April 26, 2025 /PRNewswire/ -- CGTN published an article on China's latest leadership meeting on the economic situation and…
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests…
April 11, 2025 16:01 ET | Source: argenx SE April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx…
